Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
About this item
Full title
Author / Creator
Publisher
Switzerland: MDPI
Journal title
Language
English
Formats
Publication information
Publisher
Switzerland: MDPI
Subjects
More information
Scope and Contents
Contents
Systemic light-chain (AL) amyloidosis is caused by a small B cell, most commonly a plasma cell (PC), clone that produces toxic light chains (LC) that cause organ dysfunction and deposits in tissues. Due to the production of amyloidogenic, misfolded LC, AL PCs display peculiar biologic features. The small, indolent plasma cell clone is an ideal targ...
Alternative Titles
Full title
Daratumumab in the Treatment of Light-Chain (AL) Amyloidosis
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1afdb865742b4785b3a47a10b8e43e4e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1afdb865742b4785b3a47a10b8e43e4e
Other Identifiers
ISSN
2073-4409
E-ISSN
2073-4409
DOI
10.3390/cells10030545
